GSK plc (LON:GSK) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of GSK plc (LON:GSK) have received a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is GBX 1,842.50 ($23.98).

Several equities research analysts have recently issued reports on GSK shares. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 1,850 ($24.08) price target on shares of GSK in a report on Tuesday, September 3rd. Berenberg Bank reissued a “buy” rating and issued a GBX 1,820 ($23.69) target price on shares of GSK in a research report on Tuesday, September 10th. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Monday, July 29th. Finally, Shore Capital reiterated a “buy” rating on shares of GSK in a report on Wednesday, August 28th.

Insider Transactions at GSK

In other news, insider Jonathan Symonds acquired 7,150 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of GBX 1,394 ($18.15) per share, with a total value of £99,671 ($129,746.16). In related news, insider Jonathan Symonds acquired 7,150 shares of GSK stock in a transaction on Wednesday, October 30th. The stock was purchased at an average cost of GBX 1,394 ($18.15) per share, with a total value of £99,671 ($129,746.16). Also, insider Elizabeth (Liz) McKee Anderson acquired 446 shares of the firm’s stock in a transaction on Monday, September 23rd. The stock was bought at an average price of GBX 2,051 ($26.70) per share, for a total transaction of £9,147.46 ($11,907.65). Insiders have acquired 7,604 shares of company stock valued at $10,893,886 in the last three months. 1.61% of the stock is owned by corporate insiders.

GSK Price Performance

Shares of GSK opened at GBX 1,376 ($17.91) on Thursday. The business’s 50-day moving average is GBX 1,528.84 and its 200-day moving average is GBX 1,588.89. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. The company has a market capitalization of £56.14 billion, a price-to-earnings ratio of 1,212.83, a P/E/G ratio of 1.24 and a beta of 0.31. GSK has a fifty-two week low of GBX 1,368 ($17.81) and a fifty-two week high of GBX 1,823.50 ($23.74).

GSK Announces Dividend

The company also recently announced a dividend, which will be paid on Thursday, January 9th. Stockholders of record on Thursday, November 14th will be issued a GBX 15 ($0.20) dividend. This represents a dividend yield of 1.03%. The ex-dividend date of this dividend is Thursday, November 14th. GSK’s payout ratio is 5,309.73%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.